The impact of demographic, clinical, genetic, and imaging variables on tau PET status.
Alzheimer’s disease
Aβ
Dementia
MCI
PET
Tau
Journal
European journal of nuclear medicine and molecular imaging
ISSN: 1619-7089
Titre abrégé: Eur J Nucl Med Mol Imaging
Pays: Germany
ID NLM: 101140988
Informations de publication
Date de publication:
07 2021
07 2021
Historique:
received:
24
09
2020
accepted:
27
10
2020
pubmed:
21
11
2020
medline:
29
6
2021
entrez:
20
11
2020
Statut:
ppublish
Résumé
A substantial proportion of amyloid-β (Aβ)+ patients with clinically diagnosed Alzheimer's disease (AD) dementia and mild cognitive impairment (MCI) are tau PET-negative, while some clinically diagnosed non-AD neurodegenerative disorder (non-AD) patients or cognitively unimpaired (CU) subjects are tau PET-positive. We investigated which demographic, clinical, genetic, and imaging variables contributed to tau PET status. We included 2338 participants (430 Aβ+ AD dementia, 381 Aβ+ MCI, 370 non-AD, and 1157 CU) who underwent [ Tau PET positivity in the temporal meta-ROI was 88.6% for AD dementia, 46.5% for MCI, 9.5% for non-AD, and 6.1% for CU. Among Aβ+ participants with AD dementia and MCI, lower age, MMSE score, and AD-signature cortical thickness showed the strongest associations with tau PET positivity. In non-AD and CU participants, presence of Aβ was the strongest predictor of a positive tau PET scan. We identified several demographic, clinical, and neurobiological factors that are important to explain the variance in tau PET retention observed across the AD pathological continuum, non-AD neurodegenerative disorders, and cognitively unimpaired persons.
Identifiants
pubmed: 33215319
doi: 10.1007/s00259-020-05099-w
pii: 10.1007/s00259-020-05099-w
pmc: PMC8131404
mid: NIHMS1662667
doi:
Substances chimiques
Amyloid beta-Peptides
0
tau Proteins
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2245-2258Subventions
Organisme : EPA
ID : EP-W-17-011
Pays : United States
Organisme : NIA NIH HHS
ID : U19 AG063911
Pays : United States
Organisme : NIA NIH HHS
ID : P01 AG019724
Pays : United States
Organisme : NINDS NIH HHS
ID : R01 NS050915
Pays : United States
Organisme : NIA NIH HHS
ID : K99 AG065501
Pays : United States
Organisme : NIA NIH HHS
ID : U01 AG024904
Pays : United States
Organisme : NIA NIH HHS
ID : R01 AG038791
Pays : United States
Organisme : NIA NIH HHS
ID : P30 AG062422
Pays : United States
Organisme : NIA NIH HHS
ID : U19 AG024904
Pays : United States
Organisme : NIA NIH HHS
ID : R01 AG045611
Pays : United States
Organisme : NIDCD NIH HHS
ID : K24 DC015544
Pays : United States
Références
Selkoe DJ. The molecular pathology of Alzheimer's disease. Neuron. 1991;6:487–98. https://doi.org/10.1016/0896-6273(91)90052-2 .
doi: 10.1016/0896-6273(91)90052-2
pubmed: 1673054
Leuzy A, Chiotis K, Lemoine L, Gillberg PG, Almkvist O, Rodriguez-Vieitez E, et al. Tau PET imaging in neurodegenerative tauopathies-still a challenge. Mol Psychiatry. 2019;24:1112–34. https://doi.org/10.1038/s41380-018-0342-8 .
doi: 10.1038/s41380-018-0342-8
pubmed: 30635637
pmcid: 6756230
US Food & Drug administration. https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-image-tau-pathology-patients-being-evaluated-alzheimers-disease . Accessed 28 May 2020.
Jack CR, Wiste HJ, Botha H, Weigand SD, Therneau TM, Knopman DS, et al. The bivariate distribution of amyloid-beta and tau: relationship with established neurocognitive clinical syndromes. Brain. 2019;142:3230–42. https://doi.org/10.1093/brain/awz268 .
doi: 10.1093/brain/awz268
pubmed: 31501889
pmcid: 6763736
Leuzy A, Smith R, Ossenkoppele R, Santillo A, Borroni E, Klein G, et al. Diagnostic performance of RO948 F 18 tau positron emission tomography in the differentiation of Alzheimer disease from other neurodegenerative disorders. JAMA Neurol. 2020. https://doi.org/10.1001/jamaneurol.2020.0989 .
Ossenkoppele R, Rabinovici GD, Smith R, Cho H, Scholl M, Strandberg O, et al. Discriminative accuracy of [18F]flortaucipir positron emission tomography for Alzheimer disease vs other neurodegenerative disorders. JAMA. 2018;320:1151–62. https://doi.org/10.1001/jama.2018.12917 .
doi: 10.1001/jama.2018.12917
pubmed: 30326496
pmcid: 6233630
Pontecorvo MJ, Devous MD Sr, Navitsky M, Lu M, Salloway S, Schaerf FW, et al. Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition. Brain. 2017;140:748–63. https://doi.org/10.1093/brain/aww334 .
doi: 10.1093/brain/aww334
pubmed: 28077397
pmcid: 5382945
Bevan-Jones WR, Cope TE, Jones PS, Passamonti L, Hong YT, Fryer TD, et al. [(18)F]AV-1451 binding in vivo mirrors the expected distribution of TDP-43 pathology in the semantic variant of primary progressive aphasia. J Neurol Neurosurg Psychiatry. 2018;89:1032–7. https://doi.org/10.1136/jnnp-2017-316402 .
doi: 10.1136/jnnp-2017-316402
pubmed: 28912300
Schonhaut DR, McMillan CT, Spina S, Dickerson BC, Siderowf A, Devous MD Sr, et al. (18) F-flortaucipir tau positron emission tomography distinguishes established progressive supranuclear palsy from controls and Parkinson disease: a multicenter study. Ann Neurol. 2017;82:622–34. https://doi.org/10.1002/ana.25060 .
doi: 10.1002/ana.25060
pubmed: 28980714
pmcid: 5665658
Buckley RF, Mormino EC, Rabin JS, Hohman TJ, Landau S, Hanseeuw BJ, et al. Sex differences in the Association of Global Amyloid and Regional Tau Deposition Measured by positron emission tomography in clinically normal older adults. JAMA Neurol. 2019;76:542–51. https://doi.org/10.1001/jamaneurol.2018.4693 .
doi: 10.1001/jamaneurol.2018.4693
pubmed: 30715078
pmcid: 6515599
Cho H, Choi JY, Hwang MS, Lee JH, Kim YJ, Lee HM, et al. Tau PET in Alzheimer disease and mild cognitive impairment. Neurology. 2016;87:375–83. https://doi.org/10.1212/WNL.0000000000002892 .
doi: 10.1212/WNL.0000000000002892
pubmed: 27358341
Graff-Radford J, Arenaza-Urquijo EM, Knopman DS, Schwarz CG, Brown RD, Rabinstein AA, et al. White matter hyperintensities: relationship to amyloid and tau burden. Brain. 2019;142:2483–91. https://doi.org/10.1093/brain/awz162 .
doi: 10.1093/brain/awz162
pubmed: 31199475
pmcid: 6658846
La Joie R, Visani AV, Baker SL, Brown JA, Bourakova V, Cha J, et al. Prospective longitudinal atrophy in Alzheimer’s disease correlates with the intensity and topography of baseline tau-PET. Sci Transl Med. 2020;12. https://doi.org/10.1126/scitranslmed.aau5732 .
Mattsson N, Ossenkoppele R, Smith R, Strandberg O, Ohlsson T, Jogi J, et al. Greater tau load and reduced cortical thickness in APOE epsilon4-negative Alzheimer’s disease: a cohort study. Alzheimers Res Ther. 2018;10:77. https://doi.org/10.1186/s13195-018-0403-x .
doi: 10.1186/s13195-018-0403-x
pubmed: 30086796
pmcid: 6081879
McSweeney M, Pichet Binette A, Meyer PF, Gonneaud J, Bedetti C, Ozlen H, et al. Intermediate flortaucipir uptake is associated with Abeta-PET and CSF tau in asymptomatic adults. Neurology. 2020;94:e1190–e200. https://doi.org/10.1212/WNL.0000000000008905 .
doi: 10.1212/WNL.0000000000008905
pubmed: 32015176
Ossenkoppele R, Lyoo CH, Jester-Broms J, Sudre CH, Cho H, Ryu YH, et al. Assessment of demographic, genetic, and imaging variables associated with brain resilience and cognitive resilience to pathological tau in patients with Alzheimer disease. JAMA Neurol. 2020;77:632–42. https://doi.org/10.1001/jamaneurol.2019.5154 .
doi: 10.1001/jamaneurol.2019.5154
pubmed: 32091549
Ossenkoppele R, Lyoo CH, Sudre CH, van Westen D, Cho H, Ryu YH, et al. Distinct tau PET patterns in atrophy-defined subtypes of Alzheimer’s disease. Alzheimers Dement. 2020;16:335–44. https://doi.org/10.1016/j.jalz.2019.08.201 .
doi: 10.1016/j.jalz.2019.08.201
pubmed: 31672482
pmcid: 7012375
Ossenkoppele R, Schonhaut DR, Scholl M, Lockhart SN, Ayakta N, Baker SL, et al. Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer’s disease. Brain. 2016;139:1551–67. https://doi.org/10.1093/brain/aww027 .
doi: 10.1093/brain/aww027
pubmed: 26962052
pmcid: 5006248
Ossenkoppele R, Smith R, Ohlsson T, Strandberg O, Mattsson N, Insel PS, et al. Associations between tau, Abeta, and cortical thickness with cognition in Alzheimer disease. Neurology. 2019;92:e601–e12. https://doi.org/10.1212/WNL.0000000000006875 .
doi: 10.1212/WNL.0000000000006875
pubmed: 30626656
pmcid: 6382060
Scholl M, Ossenkoppele R, Strandberg O, Palmqvist S, Swedish Bio F, Jogi J, et al. Distinct 18F-AV-1451 tau PET retention patterns in early- and late-onset Alzheimer’s disease. Brain. 2017;140:2286–94. https://doi.org/10.1093/brain/awx171 .
doi: 10.1093/brain/awx171
pubmed: 29050382
Therriault J, Benedet AL, Pascoal TA, Mathotaarachchi S, Chamoun M, Savard M, et al. Association of apolipoprotein E epsilon4 with medial temporal tau independent of amyloid-beta. JAMA Neurol. 2020;77:470–9. https://doi.org/10.1001/jamaneurol.2019.4421 .
doi: 10.1001/jamaneurol.2019.4421
pubmed: 31860000
Timmers T, Ossenkoppele R, Wolters EE, Verfaillie SCJ, Visser D, Golla SSV, et al. Associations between quantitative [(18)F]flortaucipir tau PET and atrophy across the Alzheimer’s disease spectrum. Alzheimers Res Ther. 2019;11:60. https://doi.org/10.1186/s13195-019-0510-3 .
doi: 10.1186/s13195-019-0510-3
pubmed: 31272512
pmcid: 6610969
Whitwell JL, Graff-Radford J, Tosakulwong N, Weigand SD, Machulda MM, Senjem ML, et al. Imaging correlations of tau, amyloid, metabolism, and atrophy in typical and atypical Alzheimer’s disease. Alzheimers Dement. 2018;14:1005–14. https://doi.org/10.1016/j.jalz.2018.02.020 .
doi: 10.1016/j.jalz.2018.02.020
pubmed: 29605222
pmcid: 6097955
Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, et al. The diagnosis of mild cognitive impairment due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7:270–9. https://doi.org/10.1016/j.jalz.2011.03.008 .
doi: 10.1016/j.jalz.2011.03.008
pubmed: 21514249
pmcid: 3312027
McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, Kawas CH, et al. The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7:263–9. https://doi.org/10.1016/j.jalz.2011.03.005 .
doi: 10.1016/j.jalz.2011.03.005
pubmed: 21514250
pmcid: 3312024
Jack CR Jr, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, et al. NIA-AA research framework: toward a biological definition of Alzheimer’s disease. Alzheimers Dement. 2018;14:535–62. https://doi.org/10.1016/j.jalz.2018.02.018 .
doi: 10.1016/j.jalz.2018.02.018
pubmed: 29653606
pmcid: 5958625
Weiner MW, Veitch DP. Introduction to special issue: overview of Alzheimer’s disease neuroimaging initiative. Alzheimers Dement. 2015;11:730–3. https://doi.org/10.1016/j.jalz.2015.05.007 .
doi: 10.1016/j.jalz.2015.05.007
pubmed: 26194308
pmcid: 5536175
Sled JGZA, Evans AC. A nonparametric method for automatic correction of intensity nonuniformity in MRI data. IEEE Trans Med Imaging. 1998;17:10.
Segonne F, Dale AM, Busa E, Glessner M, Salat D, Hahn HK, et al. A hybrid approach to the skull stripping problem in MRI. Neuroimage. 2004;22:1060–75. https://doi.org/10.1016/j.neuroimage.2004.03.032 .
doi: 10.1016/j.neuroimage.2004.03.032
pubmed: 15219578
Fischl B, Salat DH, Busa E, Albert M, Dieterich M, Haselgrove C, et al. Whole brain segmentation: automated labeling of neuroanatomical structures in the human brain. Neuron. 2002;33:341–55. https://doi.org/10.1016/s0896-6273(02)00569-x .
doi: 10.1016/s0896-6273(02)00569-x
pubmed: 11832223
Fischl B, Dale AM. Measuring the thickness of the human cerebral cortex from magnetic resonance images. Proc Natl Acad Sci U S A. 2000;97:11050–5. https://doi.org/10.1073/pnas.200033797 .
doi: 10.1073/pnas.200033797
pubmed: 10984517
pmcid: 27146
Jack CR Jr, Wiste HJ, Weigand SD, Therneau TM, Lowe VJ, Knopman DS, et al. Defining imaging biomarker cut points for brain aging and Alzheimer’s disease. Alzheimers Dement. 2017;13:205–16. https://doi.org/10.1016/j.jalz.2016.08.005 .
doi: 10.1016/j.jalz.2016.08.005
pubmed: 27697430
Maass A, Landau S, Baker SL, Horng A, Lockhart SN, La Joie R, et al. Comparison of multiple tau-PET measures as biomarkers in aging and Alzheimer’s disease. Neuroimage. 2017;157:448–63. https://doi.org/10.1016/j.neuroimage.2017.05.058 .
doi: 10.1016/j.neuroimage.2017.05.058
pubmed: 28587897
pmcid: 5814575
Sudre CH, Cardoso MJ, Bouvy WH, Biessels GJ, Barnes J, Ourselin S. Bayesian model selection for pathological neuroimaging data applied to white matter lesion segmentation. IEEE Trans Med Imaging. 2015;34:2079–102. https://doi.org/10.1109/TMI.2015.2419072 .
doi: 10.1109/TMI.2015.2419072
pubmed: 25850086
Cleveland WS. Robust locally weighted regression and smoothing scatterplots. J Am Stat Assoc. 1979;74:829–36. https://doi.org/10.2307/2286407 .
doi: 10.2307/2286407
Nelson PT, Dickson DW, Trojanowski JQ, Jack CR, Boyle PA, Arfanakis K, et al. Limbic-predominant age-related TDP-43 encephalopathy (LATE): consensus working group report. Brain. 2019;142:1503–27. https://doi.org/10.1093/brain/awz099 .
doi: 10.1093/brain/awz099
pubmed: 31039256
pmcid: 6536849
Karanth S, Nelson PT, Katsumata Y, Kryscio RJ, Schmitt FA, Fardo DW, et al. Prevalence and clinical phenotype of quadruple misfolded proteins in older adults. JAMA Neurol. 2020. https://doi.org/10.1001/jamaneurol.2020.1741 .
Hardy J. The amyloid hypothesis for Alzheimer’s disease: a critical reappraisal. J Neurochem. 2009;110:1129–34. https://doi.org/10.1111/j.1471-4159.2009.06181.x .
doi: 10.1111/j.1471-4159.2009.06181.x
pubmed: 19457065
Kirkwood TB. Understanding the odd science of aging. Cell. 2005;120:437–47. https://doi.org/10.1016/j.cell.2005.01.027 .
doi: 10.1016/j.cell.2005.01.027
pubmed: 15734677
Jellinger KA, Attems J. Prevalence of dementia disorders in the oldest-old: an autopsy study. Acta Neuropathol. 2010;119:421–33. https://doi.org/10.1007/s00401-010-0654-5 .
doi: 10.1007/s00401-010-0654-5
pubmed: 20204386
Ossenkoppele R, Jansen WJ, Rabinovici GD, Knol DL, van der Flier WM, van Berckel BN, et al. Prevalence of amyloid PET positivity in dementia syndromes: a meta-analysis. JAMA. 2015;313:1939–49. https://doi.org/10.1001/jama.2015.4669 .
doi: 10.1001/jama.2015.4669
pubmed: 25988463
pmcid: 4517678
Honer M, Gobbi L, Knust H, Kuwabara H, Muri D, Koerner M, et al. Preclinical evaluation of (18)F-RO6958948, (11)C-RO6931643, and (11)C-RO6924963 as novel PET radiotracers for imaging tau aggregates in Alzheimer disease. J Nucl Med. 2018;59:675–81. https://doi.org/10.2967/jnumed.117.196741 .
doi: 10.2967/jnumed.117.196741
pubmed: 28970331
pmcid: 5932750
Marquie M, Normandin MD, Vanderburg CR, Costantino IM, Bien EA, Rycyna LG, et al. Validating novel tau positron emission tomography tracer [F-18]-AV-1451 (T807) on postmortem brain tissue. Ann Neurol. 2015;78:787–800. https://doi.org/10.1002/ana.24517 .
doi: 10.1002/ana.24517
pubmed: 26344059
pmcid: 4900162
Fleisher AS, Pontecorvo MJ, Devous MD Sr, Lu M, Arora AK, Truocchio SP, et al. Positron emission tomography imaging with [18F]flortaucipir and postmortem assessment of Alzheimer disease neuropathologic changes. JAMA Neurol. 2020. https://doi.org/10.1001/jamaneurol.2020.0528 .
Bejanin A, Schonhaut DR, La Joie R, Kramer JH, Baker SL, Sosa N, et al. Tau pathology and neurodegeneration contribute to cognitive impairment in Alzheimer’s disease. Brain. 2017;140:3286–300. https://doi.org/10.1093/brain/awx243 .
doi: 10.1093/brain/awx243
pubmed: 29053874
pmcid: 5841139
Gordon BA, Blazey TM, Christensen J, Dincer A, Flores S, Keefe S, et al. Tau PET in autosomal dominant Alzheimer’s disease: relationship with cognition, dementia and other biomarkers. Brain. 2019;142:1063–76. https://doi.org/10.1093/brain/awz019 .
doi: 10.1093/brain/awz019
pubmed: 30753379
pmcid: 6439328
Scott MR, Hampton OL, Buckley RF, Chhatwal JP, Hanseeuw BJ, Jacobs HI, et al. Inferior temporal tau is associated with accelerated prospective cortical thinning in clinically normal older adults. Neuroimage. 2020;220:116991. https://doi.org/10.1016/j.neuroimage.2020.116991 .
doi: 10.1016/j.neuroimage.2020.116991
pubmed: 32512123
pmcid: 7572623
Jack CR Jr, Wiste HJ, Therneau TM, Weigand SD, Knopman DS, Mielke MM, et al. Associations of amyloid, tau, and neurodegeneration biomarker profiles with rates of memory decline among individuals without dementia. JAMA. 2019;321:2316–25. https://doi.org/10.1001/jama.2019.7437 .
doi: 10.1001/jama.2019.7437
pubmed: 31211344
pmcid: 6582267
Ramanan VK, Castillo AM, Knopman DS, Graff-Radford J, Lowe VJ, Petersen RC, et al. Association of apolipoprotein E varepsilon4, educational level, and sex with tau deposition and tau-mediated metabolic dysfunction in older adults. JAMA Netw Open. 2019;2:e1913909. https://doi.org/10.1001/jamanetworkopen.2019.13909 .
doi: 10.1001/jamanetworkopen.2019.13909
pubmed: 31642932
pmcid: 6820045
Beach TG, Monsell SE, Phillips LE, Kukull W. Accuracy of the clinical diagnosis of Alzheimer disease at National Institute on Aging Alzheimer Disease Centers, 2005-2010. J Neuropathol Exp Neurol. 2012;71:266–73. https://doi.org/10.1097/NEN.0b013e31824b211b .
doi: 10.1097/NEN.0b013e31824b211b
pubmed: 22437338
pmcid: 3331862
Busche MA, Hyman BT. Synergy between amyloid-beta and tau in Alzheimer’s disease. Nat Neurosci. 2020. https://doi.org/10.1038/s41593-020-0687-6 .
Smith R, Scholl M, Leuzy A, Jogi J, Ohlsson T, Strandberg O, et al. Head-to-head comparison of tau positron emission tomography tracers [(18)F]flortaucipir and [(18)F]RO948. Eur J Nucl Med Mol Imaging. 2020;47:342–54. https://doi.org/10.1007/s00259-019-04496-0 .
doi: 10.1007/s00259-019-04496-0
pubmed: 31612245